| First Author | Zhang S | Year | 2023 |
| Journal | Sci Signal | Volume | 16 |
| Issue | 793 | Pages | eade6325 |
| PubMed ID | 37433006 | Mgi Jnum | J:362060 |
| Mgi Id | MGI:7868345 | Doi | 10.1126/scisignal.ade6325 |
| Citation | Zhang S, et al. (2023) TRPM7 kinase activity induces amyloid-beta degradation to reverse synaptic and cognitive deficits in mouse models of Alzheimer's disease. Sci Signal 16(793):eade6325 |
| abstractText | Altered abundance or activity of the dual-function transient receptor potential melastatin-like 7 (TRPM7) protein is implicated in neurodegenerative disorders, including Alzheimer's disease (AD). Toxic aggregation of amyloid-beta (Abeta) in neurons is implicated in AD pathology. Here, we found that the kinase activity of TRPM7 is important to stimulate the degradation of Abeta. TRPM7 expression was decreased in hippocampal tissue samples from patients with AD and two mouse models of AD (APP/PS1 and 5XFAD). In cultures of hippocampal neurons from mice, overexpression of full-length TRPM7 or of its functional kinase domain M7CK prevented synapse loss induced by exogenous Abeta. In contrast, this neuroprotection was not afforded by overexpression of either the functional ion channel portion alone or a TRPM7 mutant lacking kinase activity. M7CK overexpression in the hippocampus of young and old 5XFAD mice prevented and reversed, respectively, memory deficits, synapse loss, and Abeta plaque accumulation. In both neurons and mice, M7CK interacted with and activated the metalloprotease MMP14 to promote Abeta degradation. Thus, TRPM7 loss in patients with AD may contribute to the associated Abeta pathology. |
